FATE · Fate Therapeutics Inc
United States · RS rating 45 · As of 2026-11-03
| Price | 2.04 USD |
|---|---|
| 1-day change | +1.5% |
| RS rating (overall / 1M / 3M / 12M) | 45 / 26 / 29 / 85 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 21 / 30 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | -21.4% |
| Distance from 52-week high | +34.4% |
| Market cap (USD) | $153.5M |